spacer
The Healthcare Sales & Marketing Network celebrates 26 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  formoterol 

 HSMN NewsFeed - 31 Jul 2023
Viatris Announces Launch of Breyna(TM) (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol, the First FDA-Approved Generic Version of Symbicort(R) for People with Asthma and Chronic Obstructive Pulmonary Disease, in Partnership with Kindeva
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 1 Sep 2016
Sunovion Pharmaceuticals to Acquire Cynapsus Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Jun 2016
Theravance Biopharma Highlights Positive Top-Line Results From Pivotal Phase 3 FULFIL Study of the Closed Triple Announced by GlaxoSmithKline and Innoviva
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2014
Teva Receives European Marketing Authorization for DuoResp Spiromax(R) for the Treatment of Asthma and COPD
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Feb 2014
Teva Receives CHMP Positive Opinion for DuoResp(R) Spiromax(R) for the Treatment of Patients Diagnosed with Asthma and COPD in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Nov 2012
Pearl Therapeutics Raises $65 Million Series D to Start PT003 Phase 3
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Sep 2012
Sunovion Pharmaceuticals Inc. Completes Acquisition of Elevation Pharmaceuticals, Inc.
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Aug 2012
Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc.
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 10 May 2012
SYMBICORT(R) (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows Similar Safety Profile When Compared to Budesonide Monotherapy in African-American Patients with Asthma
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2010
Pearl Therapeutics Raises $69 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 15 Jul 2010
Sepracor Inc. to Become Sunovion Pharmaceuticals Inc.
Biopharmaceuticals
 HSMN NewsFeed - 24 Jun 2010
FDA Approves Merck's DULERA(R) (mometasone furoate and formoterol fumarate dihydrate) Inhalation Aerosol for the Treatment of Asthma in Patients 12 Years of Age and Older
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Feb 2010
Sepracor Announces New Management Changes and Plans for Merger with Dainippon Sumitomo Pharma America
Biopharmaceuticals Mergers & Acquisitions Personnel
 HSMN NewsFeed - 17 Dec 2009
Sepracor Granted Patent Term Extension for LUNESTA(R) and Provides Update on LUNESTA Pediatric Studies
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Sep 2009
Dainippon Sumitomo Pharma to Acquire Sepracor for U.S. $23.00 Per Share in an All-Cash Tender Offer Valued at Approximately U.S. $2.6 Billion
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 May 2009
Budesonide/Formoterol Plus Tiotropium Improves the Quality of Life of Patients With Severe COPD
Biopharmaceuticals
 HSMN NewsFeed - 19 May 2009
Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2009
Skyepharma PLC Announces Regulatory Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Oct 2008
European Medicines Agency (EMEA) Issues Positive Opinion For LUNIVIA(R) (Eszopiclone) Marketing Authorization Application (MAA) In Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Sep 2008
New Data Show Efficacy and Safety of Eslicarbazepine Acetate in the Treatment of Epilepsy
Biopharmaceuticals Neurology
 HSMN NewsFeed - 2 Aug 2008
Inhaler Devices are Still a Major Hurdle in Asthma and COPD Treatment
Biopharmaceuticals Devices Drug Delivery
 HSMN NewsFeed - 19 Jun 2008
Sepracor Announces Phase III Data for Eslicarbazepine Acetate Presented at Ninth Eilat Conference on New Anti-Epileptic Drugs
Biopharmaceuticals Neurology
 HSMN NewsFeed - 4 Jun 2008
AstraZeneca Submits an sNDA for SYMBICORT(R) for the Treatment of Asthma in Children as Young as Age Six
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jun 2008
Sepracor Completes Acquisition of Oryx Pharmaceuticals and Expands Operations in Canada
Biopharmaceuticals
 HSMN NewsFeed - 12 May 2008
LUNESTA(R) Study of Patients with Insomnia and Co-Morbid Generalized Anxiety Disorder (GAD) Published in Archives of General Psychiatry
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2008
Sepracor and Arrow Sign Global License and Development Agreement Covering Technology to Enhance Ciclesonide and BROVANA(R) Franchises
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 May 2008
Sepracor Announces Final Settlement of XOPENEX(R) Inhalation Solution Patent Infringement Litigation with Breath Limited
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 May 2008
Sepracor and Arrow Sign Global License and Development Agreement for XOPENEX(R)/Ipratropium Inhalation Solution Combination
Biopharmaceuticals Licensing
 HSMN NewsFeed - 1 May 2008
Sepracor to Acquire Oryx Pharmaceuticals Inc. and Expand Commercial Operations into Canada
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 17 Mar 2008
Sepracor Presents OMNARIS(TM) HFA Nasal Aerosol Large-Scale Phase II Study Data at American Academy of Allergy Asthma and Immunology (AAAAI)
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
Sepracor Presents Safety Data on OMNARIS(TM)AQ and OMNARIS(TM) HFA Nasal Sprays at American Academy of Allergy Asthma and Immunology (AAAAI)
Biopharmaceuticals
 HSMN NewsFeed - 28 Jan 2008
Sepracor Acquires Exclusive U.S. Rights to Nycomed's ALVESCO(R) HFA and OMNARIS(TM) AQ Products as Well as Ciclesonide Pipeline
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 2 Jan 2008
Sepracor Inc. and Bial Announce Exclusive Licensing Agreement for Development and Commercialization of Anti-Epileptic Compound in United States and Canada
Biopharmaceuticals Neurology Licensing
 HSMN NewsFeed - 5 Nov 2007
Sepracor Inc. Announces the Establishment of a Unique Product-Specific Billing Code (or J-Code) for BROVANA(R)
Biopharmaceuticals Reimbursement
 HSMN NewsFeed - 24 Oct 2007
Two Clinical Trials for Nebulized Formoterol Fumarate on Long-Term and Cardiovascular Safety in Treating COPD
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
Clinical Trial Data on the Safety and Efficacy of Concomitant Formoterol Fumarate/ Tiotropium Treatment for COPD
Biopharmaceuticals
 HSMN NewsFeed - 8 Oct 2007
Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
Biopharmaceuticals
 HSMN NewsFeed - 25 Sep 2007
Critical Therapeutics Highlights Near-Term Milestones to Drive Commercial Success and Clinical Development
Biopharmaceuticals
 HSMN NewsFeed - 11 Sep 2007
Sepracor Inc. and GlaxoSmithKline Announce International Alliance for Commercialization of LUNIVIA(R) (LUNESTA(R) in U.S.)
Biopharmaceuticals
 HSMN NewsFeed - 27 Jul 2007
Sepracor Submits LUNIVIA(R) (LUNESTA(R) in U.S.) Marketing Authorization Application (MAA) for Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Jul 2007
Sepracor Inc. and Eisai Co. Ltd. Announce Partnership for Development and Commercialization of LUNESTA(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2007
Critical Therapeutics and Dey, L.P. Complete Definitive Co-Promotion Agreement for Perforomist(TM) Inhalation Solution
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 25 Jun 2007
AstraZeneca Announces SYMBICORT(R) is Now Available in the U.S.
Biopharmaceuticals
 HSMN NewsFeed - 21 May 2007
Clinical Trial Data for Perforomist(TM) (Formoterol Fumarate) Inhalation Solution Presented at International ATS Conference
Biopharmaceuticals
 HSMN NewsFeed - 11 May 2007
FDA Approves Dey, L.P.'s Perforomist(TM) (Formoterol Fumarate) Inhalation Solution for Maintenance Treatment of COPD
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Apr 2007
BROVANA(TM) Inhalation Solution Now Available by Prescription for Patients with Chronic Obstructive Pulmonary Disease (COPD)
Biopharmaceuticals
 HSMN NewsFeed - 18 Dec 2006
SkyePharma PLC announces FDA approves FORADIL(R) CERTIHALER(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2006
Approved Asthma Therapy SYMBICORT Improves Lung Function Safely and Effectively
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution Study Data Presented at American College of Chest Physicians Annual Conference
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2006
FDA Approves Sepracor's BROVANA(TM) (Arformoterol Tartrate) Inhalation Solution for Chronic Obstructive Pulmonary Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Sep 2006
SkyePharma and Mundipharma Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in Europe
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 May 2006
Kos and SkyePharma Sign Exclusive License Agreement for the Marketing and Distribution of Flutiform(TM) in the United States
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 8 May 2006
SkyePharma and Kos Announce Exclusive Licence Agreement for Marketing and Distribution of Flutiform(TM) in the United States
Biopharmaceuticals Licensing Distribution
Return to NewsFeed  

 Additional items found! 20

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 20 additional stories matching:
formoterol
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.